By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Mizuho's price target would suggest a potential downside of 40.61% from the company's current price.
A number of other research firms have also recently issued reports on VRX. Wells Fargo & Company reiterated an "underperform" rating on shares of Valeant Pharmaceuticals International in a report on Monday, June 12th. BMO Capital Markets lifted their price target on Valeant Pharmaceuticals International to $21.00 in a report on Wednesday, March 1st. Vetr cut shares of Valeant Pharmaceuticals International from a "strong-buy" rating to a "buy" rating and set a $14.82 price target for the company.in a research report on Monday, May 22nd. J P Morgan Chase & Co reaffirmed a "hold" rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 9th. Scotiabank lowered their price target on shares of Valeant Pharmaceuticals International from $15.00 to $12.00 and set a "sector perform" rating for the company in a research report on Wednesday, April 26th.
Monday morning rain, with afternoon sun
Notably cooler conditions are expected for the latter half of the work week and through the weekend. Today's forecast calls for scattered showers, with thunderstorms also possible after 11 a.m.
Among 25 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 16 Hold. Ftb Advsrs reported 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock declined 0.22% or $0.03 reaching $13.44 per share. Armstrong Henry H Associates Inc who had been investing in Valeant Pharmaceuticals for a number of months, seems to be less bullish one the $4.82 billion market cap company. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. The company's 50-day moving average price is $16.72 and its 200 day moving average price is $17.24. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since June 20, 2016 and is downtrending. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the consensus estimate of $0.87 by $1.93. For our stock under consideration here, Valeant Pharmaceuticals International, Inc. The company had revenue of $2.11 billion during the quarter, compared to analysts' expectations of $2.17 billion. During the same period in the previous year, the firm earned ($1.08) EPS.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and global copyright & trademark law. Pinebridge Invs Limited Partnership reported 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Cosby Accuser Andrea Constand Thanks Supporters for 'Love & Kindness'
Bill Cosby exits the Montgomery County Courthouse after a mistrial was declared in Norristown, Pa ., Saturday, June 17, 2017. Cosby acknowledged that he had cheated on his wife with Constand, but he said that their relationship was consensual.
In related news, Director Schutter Richard U. De purchased 20,000 shares of the stock in a transaction on Thursday, May 11th. The shares were acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. Institutional investors own 50.45% of the company's stock. It dropped, as 82 investors sold VRX shares while 87 reduced holdings. Equities analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year. Prudential Public Ltd Company accumulated 75,000 shares or 0% of the stock. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 9,300 shares in the last quarter. Financial Architects Inc increased its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Finally, Stonehill Capital Management LLC purchased a new stake in Valeant Pharmaceuticals International during the fourth quarter worth approximately $11,151,000. The Cypress Funds Llc holds 260,000 shares with $3.78 million value, down from 440,000 last quarter.
Paulson supported Valeant in 2014 during its unsuccessful attempt to buy Botox maker Allergan Inc., which eventually went to a rival bidder.
China welcomes Rodman's visit to N. Korea
Yun insisted on Warmbier's immediate release on humanitarian grounds , officials said, and the North Koreans agreed. Governments from around the world also looked down upon the North Korean court's decision.
- Halma plc (LON:HLMA) has analysts on the Bullish side this week
- Marathon Oil Corporation (NYSE:MRO), Post Holdings Inc (NYSE:POST)
- Perez Sells 29282 Shares of Coca-Cola Company (The) (KO) Stock
- When exactly is the first day of summer?
- Cosby faces 2nd sex assault trial after jury deadlocks
- Infantino Defends VAR At Confederations Cup
- Stock Volume Ramping Up Mid-Session: Alibaba Group Holding Limited (NYSE:BABA)
- United States says it shot down Iranian-made drone in Syria
- PGA Tour to start blood testing next season
- SP Supremo Mulayam Singh Yadav Backs NDA Presidential Nominee Ram Nath Kovind